Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of LUCAR-G39D in R/R B-cell Non-Hodgkin Lymphoma
NCT06395870Phase 1Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LUCAR-G39D cells in B-cell non-Hodgkin lymphoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Treatment-emergent Adverse Events at 2 years, Pharmacokinetics in peripheral blood at 2 years and 2 more. Started May 2024; status: recruiting.
02
Drugs
LUCAR-G39D cells
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06395870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06395870.